NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/
-- Dr. Morris C. Laster ("Dr.
Laster"), who, together with other proxy participants, beneficially
owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (Nasdaq: SCPS)
("Scopus" or the "Company"), announced today that stockholders of
the Company have elected Dr. Laster's two director nominees,
Mordechai Saar Hacham and
Joshua Levine to the Company's Board
of Directors at the Company's 2021 Annual Meeting of Stockholders
(the "Annual Meeting").
First Coast Results, Inc., the independent inspector of
elections appointed by the Company for the Annual Meeting, today
certified the final results of the election reporting that Messrs.
Hacham and Levine received the most number of votes at the Annual
Meeting, with Messrs. Hacham and Levine receiving 8,276,505 and
8,276,338 "FOR" votes, respectively, while the Company's director
nominees, Raphael (Rafi) Hofstein
and David S. Battleman, received
7,031,321 and 7,031,640 "FOR" votes, respectively. Furthermore,
stockholders of the Company voted "AGAINST" ratifying the
appointment of Citrin Cooperman & Company, LLP as the Company's
independent registered public accounting firm for the 2021 fiscal
year.
Dr. Laster said: "This victory sends a strong message to
Scopus's management and Board that stockholders want new directors
who will act as responsible, independent stewards of the
Company."
The participants in the proxy solicitation were Dr. Morris C. Laster, Chen
Laster, Gabriella Laster,
Sara Laster, Mordechai Saar Hacham and Joshua Levine.
View original
content:https://www.prnewswire.com/news-releases/dr-morris-c-laster-wins-proxy-contest-as-stockholders-elect-his-nominees-to-scopus-biopharma-inc-board-of-directors-301455235.html
SOURCE Dr. Morris C. Laster